ReviewClinical interventions in aging2025
Pathological Mechanisms and Molecular Imaging Advances in Alzheimer's Disease.
Review in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial intelligence and extracellular vesicles in oncology: towards tumor diagnosis, prediction, and therapy.Drug delivery · 2026Review
- An intelligent gradient-guided hybrid inpainting framework for brain MRI reconstruction and Alzheimer's disease classification in connected healthcare systems.Frontiers in medicine · 2026Article
- Emerging pathological mechanisms of Alzheimer's disease pathogenesis: from neuroimmune interactions to intercellular communication.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders globally, where early diagnosis plays a pivotal role in delaying disease progression and improving patient outcomes. In recent years, the rapid, multidisciplinary advances in molecular imaging and emerging technologies have significantly advanced our understanding of AD pathogenesis, early diagnosis, and intervention strategies. Imaging tools such as positron emission tomography (PET) and magnetic resonance imaging (MRI), alongside emerging technologies like retinal imaging, nanosensors, and quantum dots (QDs), are continuously enhancing AD diagnostic pathways. Studies on the gut microbiome and extracellular vesicles (EVs) offer novel insights into AD pathogenesis. Furthermore, AI-driven multimodal data fusion techniques hold great promise for improving diagnostic accuracy. Future research will increasingly focus on multi-target synergistic intervention strategies, standardization of multimodal imaging, and the integration of AI with molecular diagnostics and treatment to enable early detection and personalized precision therapy for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.